IPO initial public offering
Favicon Fierce Biotech

Avalyn brings in $300M from oversized IPO

Avalyn overshot its expectations with a $300 million IPO that the biotech will use to fund late-stage studies of its reformulated respiratory drugs.
James Waldron Apr 30, 2026 3:18am
Red and white pawns with golden arrows Employee swap or turnover concept

Drugmaker’s reputations shift amid political pressures: survey

Apr 30, 2026 1:00am
Astellas

Lessons from the eye: How cell therapy is shaping the future of regenerative medicine

Brought to you by ASTELLAS
Soriot

AstraZeneca CEO outlines conservative forecast model for MFN

Apr 29, 2026 3:08pm
AbbVie

AbbVie shrugs off new J&J competition for fast-growing Skyrizi

Apr 29, 2026 2:53pm
Teva

Teva's innovative drugs helped carry strong Q1

Apr 29, 2026 2:27pm
More News

Regeneron sees more regulatory issues, sales declines for Eylea

Apr 29, 2026 12:05pm

Shingrix surge, Exdensur flop highlight GSK CEO’s first quarter

Apr 29, 2026 10:47am

Pfizer looks to jump start Elrexfio with topline win

Apr 29, 2026 10:16am

Chiesi grows rare disease ambitions with $1.9B KalVista buyout

Apr 29, 2026 10:01am